Clinical trial · Observational
Non-interventional Treatment Patterns Study in Chronic Phase Chronic Myelogenous Leukemia (CP-CML)
Treatment Patterns and Associated Outcomes in Chronic Phase (CP) Chronic Myelogenous Leukemia (CML) Patients Who Fail Imatinib 400 mg Daily
NCT01394666CI-TRIAL-00022936completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate treatment patterns and associated outcomes for CP-CML patients who fail Imatinib 400 mg daily in a real-world setting.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Myeloid Leukemia | Chronic Myeloid Leukemia, BCR-ABL1 Positive | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- CP-CML patients who have failed Imatinib 400 mg daily
Primary outcomes (3)
- measure
- Complete Cytogenic Response (CCyR) for CP-CML patients who failed Imatinib 400 mg daily
- timeFrame
- At 3 months post treatment change
- measure
- Complete Cytogenic Response (CCyR) for CP-CML patients who failed Imatinib 400 mg daily
- timeFrame
- At 6 months post treatment change
- measure
- Complete Cytogenic Response (CCyR) for CP-CML patients who failed Imatinib 400 mg daily
- timeFrame
- At 12 months post treatment change
Secondary outcomes (8)
- measure
- Prognostic factors (clinical and demographic characteristics) that influence treatment selection for CP-CML patients who fail imatinib 400 mg daily
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Inclusion Criteria: * Adult patients (18 years or older) in Chronic phase CML patients who have been treated with Imatinib 400 mg and have failed.
References
Publications (0)
Data not yet available
No reference posted for this study.